This article reports results of 2 studies investigating
LY545694 in
pain due to
osteoarthritis (OA) of the knee and diabetic peripheral
neuropathic pain (DPNP). Study I randomized patients to either of 2 doses of
LY545694 or to placebo, and study II randomized patients to either of 3 doses of
LY545694, to
pregabalin, or to placebo. No significant differences between
LY545694 groups and placebo were observed on the primary (average
pain severity) or secondary efficacy measures in either study. Notably, study I lacked an active control, and, in study II,
pregabalin, did not separate from placebo. Treatment-emergent
nausea,
vomiting, and
dizziness were significantly more frequent in the
LY545694 groups in both trials (P⩽.05), and significantly more LY545694-treated patients discontinued because of adverse events (P<.001). Steady-state concentrations of
LY545694 were comparable in patients in both studies but were lower than exposures required for efficacy in animal models of
pain behavior. Because the active control did not separate from placebo in the DPNP study, the study was potentially failed, rather than negative. Without an active control, it is unknown whether the OA study was negative or failed. Consequently, efficacy of selective
ionotropic glutamate receptor antagonism in
chronic pain conditions may warrant further investigation. Future trials should consider different
pain conditions, contain a positive control with larger patient numbers per arm, and be conducted within a single region.